Page 9 - GENOPOLE - Rapport d'activité 2018

The three years I spent as president of Genopole, in the company of the men and women who have energized the project for more than 20 years, convinced me that beyond the issue of local development, Genopole must now and more than ever join the international scene and become an indispensable enabler for all businesses and researchers looking to have access to the European market. Doing so will play a key role in maintaining the attractiveness of Genopole for researchers, laboratories and businesses. Every day, the pertinence of the Genopole model is illustrated by such events as the arrival of international corporations like Illumina, or the world-reach partnerships signed with clusters in Canada and China that will greatly facilitate international collaborations and new business arrivals. I will continue to support this strong international momentum, beneficial to both Genopole and the attractiveness of the Region, itself very attached to the biocluster's influence and excellence. Indeed, over the past three years, the Region has faithfully provided its support to Genopole, fully aware of the need to stay on the cutting edge of tomorrow's treatments, personalized medicine and biotechnologies. Genopole celebrated its first 20 years in 2018 and is now elaborating a roadmap for its next 20 years. That is our shared ambition.
JEAN-MARC GROGNET
Vingt ans, c’est un âge où l’on peut encore rêver de son futur mais c’est aussi un âge où l’on commence à le construire « en dur ». En vingt ans, Genopole n’a rien perdu de son dynamisme initial et son ambition reste intacte : être un endroit où les acteurs du triangle de la connaissance (éducation et enseignement supérieur, recherche académique et monde économique) se côtoient et agissent ensemble pour relever avec leurs propres atouts et compétences, les défis de notre monde que sont la santé et l’environnement. Cette ambition doit dorénavant se décliner à l’échelle européenne et internationale faisant de Genopole un des bioclusters de référence dans le monde. Quatre grands axes structurent Genopole : la médecine personnalisée basée sur notre capacité accélérée à lire le génome humain, les médicaments du futur pour traiter des maladies génétiques reposant sur les thérapies génique, génomique et cellulaire, la génomique numérique qui fait appel aux sciences de l’information pour explorer plus vite et mieux les génomes et enfin les biotechnologies industrielles qui demain produiront des produits biosourcés et donneront de nouveaux moyens de traitement des sols, des eaux ou de l’air. Genopole ambitionne, pour les toutes prochaines années, que ces grands axes deviennent de véritables filières qui irrigueront notre territoire en créant connaissances et activités économiques.
Twenty years is an age at which we can still dream of our future, but at which we begin building it "for real" as well. In twenty years, Genopole has lost nothing of its initial momentum nor its ambition of being a place where actors in the triangle of knowledge (training and higher learning, academic research, and the world of business) exchange ideas and act together, all contributing their capacities and competencies, to take on the challenges our world is facing in healthcare and the environment. Today, that ambition must become not only European but also global, to make Genopole a world-reference biocluster. Genopole builds itself upon four pillars: personalized medicine impulsed by our accelerating ability to read the human genome; the future of medicine represented by gene, genomic and cell therapies to treat genetic diseases; computational genomics born of information sciences and destined to speed and improve the exploration of genomes; and finally industrial biotechnologies entrusted with the production of tomorrow's biosourced products and new means of soil, air and water treatment. For the coming years, Genopole has set its sights on turning its pillars into veritable activity sectors irrigating our territory with knowledge and economic activity.
Ancienne présidente et actuelle vice-présidente de Genopole
07
Former President and current Vice-President of Genopole
Marianne Duranton
Stéphane Beaudet
Jean-Marc Grognet
Directeur général de Genopole
CEO of Genopole